Contemporary research demonstrates that taxonomic alterations and functional perturbations in gut microbiota (microbial imbalance) significantly impact respiratory disease trajectories, particularly in COPD and allergic asthma exacerbations, as evidenced by longitudinal clinical cohort studies (Shi et al., 2021)
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
Prescription treatments require an evaluation and prescription from a licensed medical provider
Results may vary, but most people notice a reduction in cravings and appetite within the first few weeks, and visible weight loss usually begins after one or two months of consistent use